Kwikaton

Vildagliptin, the active ingredient in Kwikaton, is a DPP‑4 inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve blood glucose control when combined with diet and exercise effectively.

GNH USA supplies Kwikaton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions.

Vildagliptin is used in the treatment of type 2 diabetes mellitus, targeting the incretin pathway to improve glycemic control. - Type 2 diabetes mellitus: reduces fasting and post‑prandial blood glucose levels, helping achieve target HbA1c. - Adjunct to diet and exercise: enhances overall glycemic management when lifestyle measures are insufficient. - Combination therapy with metformin: provides additional HbA1c reduction in patients requiring multi‑drug regimens.

Vildagliptin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasopharyngitis: inflammation of the nasal passages and throat. - Headache: mild to moderate head pain. - Upper respiratory tract infection: cough, sore throat and congestion.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated pancreatic enzymes. - Severe allergic reactions: such as angioedema, Stevens‑Johnson syndrome or anaphylaxis. - Hepatic dysfunction: significant rise in liver transaminases indicating possible liver injury.

When prescribing Vildagliptin, several precautionary measures should be considered to ensure patient safety. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes regularly. - Cardiovascular disease: use with caution in patients with a history of heart failure. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Concomitant sulfonylureas or insulin: increased risk of hypoglycaemia; monitor glucose closely. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture.

Vildagliptin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Sulfonylureas or insulin: may cause significant hypoglycaemia. - Strong diuretics causing dehydration: can reduce renal clearance of the drug.

Moderate Interactions (Monitor Closely): - Rifampin: enzyme induction may lower vildagliptin plasma levels. - ACE inhibitors: combined use may increase risk of hypotension. - Warfarin: may require closer INR monitoring. - Beta‑blockers: can mask hypoglycaemia symptoms.